Spectral AI, Inc. (MDAIW)
| Market Cap | 85.29M +158.0% |
| Revenue (ttm) | 16.93M -43.5% |
| Net Income | -13.88M |
| EPS | -0.48 |
| Shares Out | 31.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 95,945 |
| Open | 0.9100 |
| Previous Close | 0.8700 |
| Day's Range | 0.7351 - 0.9300 |
| 52-Week Range | 0.2880 - 1.0100 |
| Beta | 1.16 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 12, 2026 |
About MDAIW
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation and delivers a binary prediction on the wounds capacity to heal by a specified time point in the future to assist the physician in making a more accurate, timely, and informed deci... [Read more]
News
Spectral AI price target raised to $4 from $3 at BTIG
BTIG raised the firm’s price target on Spectral AI (MDAI) to $4 from $3 and keeps a Buy rating on the shares after the company announced it received FDA clearance…
Spectral AI receives FDA De Novo clearance for DeepView System
Spectral AI (MDAI) announced that the U.S. Food and Drug Administration, FDA, granted De Novo Classification for its DeepView System. With this classification, Spectral AI is authorized to commence co...
Spectral AI Receives FDA De Novo Clearance for DeepView® System for Burn Indication
DALLAS, May 26, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more a...
Spectral AI Q1 Earnings Call Highlights
Spectral AI NASDAQ: MDAI said it remains on track toward potential U.S. regulatory clearance and commercialization of its DeepView system for burn assessment, while reporting lower first-quarter resea...
Spectral AI Earnings Call Transcript: Q1 2026
Q1 2026 saw progress in FDA engagement, BARDA funding, and leadership expansion, with R&D revenue at $4M and a net loss of $3.4M. Commercialization of DeepView is targeted for late 2026, with most BARDA revenue recognized in 2027.
Spectral AI Earnings release: Q1 2026
Spectral AI released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Spectral AI Quarterly report: Q1 2026
Spectral AI has published its Q1 2026 quarterly earnings report on May 12, 2026.
Spectral AI Announces 2026 First Quarter Financial Results
Development Work for DeepView ® Systems Continues with Support of Recently Awarded $31.7 Million of Funding from BARDA
Spectral AI Wins Small Business Innovator Award at Inaugural Texas Innovation Conference
DALLAS, April 30, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more...
Spectral AI Schedules 2026 First Quarter Financial Results and Conference Call
DALLAS, April 28, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more...
Spectral AI's DeepView® System Showcased at 2026 American Burn Association Annual Meeting
DALLAS, April 22, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more...
Spectral AI Announces Annual Meeting of Stockholders
DALLAS, April 20, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more...
Spectral AI Proxy statement: Proxy filing
Spectral AI filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Spectral AI Proxy statement: Proxy filing
Spectral AI filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Spectral AI to Feature DeepView® System at 2026 American Burn Association Annual Meeting
DALLAS, April 09, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more...
Spectral AI appoints David McGuire as CFO
Spectral AI (MDAI) announced the appointment of David McGuire as the company’s CFO, effective May 4. Prior to joining Spectral AI, he served as the chief accounting officer of Solo…
Spectral AI Names David McGuire, CPA, as Chief Financial Officer
DALLAS, April 08, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more...
Spectral AI Proxy statement: Proxy filing
Spectral AI filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Spectral AI Earnings Call Transcript: Q4 2025
2025 saw major milestones, including a pivotal FDA submission, strong BARDA support, and improved financials. 2026 revenue is forecast at $18.5M, with commercialization and significant sales growth expected in 2027–2028.
Spectral AI Annual report: Q4 2025
Spectral AI has published its Q4 2025 annual report on March 24, 2026.
Spectral AI Earnings release: Q4 2025
Spectral AI released its Q4 2025 earnings on March 24, 2026, summarizing the period's financial results.
Spectral AI reports Q4 EPS 2c with items, consensus (14c)
Reports Q4 revenue $3.8M, consensus $2.92M. Q4 EPS included a $4.0M gain in the fair value of the Company’s warrant liability. “2025 was a pivotal year for Spectral AI (MDAI),…
Spectral AI sees FY26 revenue $18.5M, consensus $14.08M
FY26 revenue view reflects the continued development of the Company’s DeepView System through the BARDA PBS Contract. This guidance does not include any material contributions from the sale of the…
Spectral AI Announces 2025 Fourth Quarter and Full Year Financial Results and Introduces Revenue Guidance for 2026
Overview Full Year Research & Development Revenue of $19.7 Million; Q4 2025 Revenue of $3.8 Million Cash Rose to $15.4 Million at December 31, 2025 DALLAS, March 24, 2026 (GLOBE NEWSWIRE) -- Spectral ...
Spectral AI receives $31.7M in funding from BARDA for DeepView System
Spectral AI (MDAI) announced that it has received $31.7M in funding from the Biomedical Advanced Research and Development Authority, or BARDA, to accelerate and support additional feature aspects for ...